Is personalized medicine a dream or a reality?
Explore this paper's citation graph
Summary
It is shown, for a number of drugs in clinical use, that genomics-guided treatment options not only are becoming feasible but are also on the cusp of showing superiority in terms of clinical outcomes as well as cost-benefit.
- Type
- review
- Published
- 2015-01-02
- Cited by
- 25
- References
- 96
- OpenAlex
- https://openalex.org/W2033806536
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24130052
Keywords
Pharmacogenomics, VKORC1, Personalized medicine, Medicine, Warfarin
References
- Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel.
- The Effect of Chronic Renal Failure on Hepatic Drug Metabolism and Drug Disposition
- SLCO1B1 variants and statin-induced myopathy--a genomewide study.
- Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
- Foye's Principles of Medicinal Chemistry
- Impact of OATP transporters on pharmacokinetics
- Impact of genetic variation in OATP transporters to drug disposition and response.
- Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
- Ethnicity-Specific Pharmacogenetics: The Case of Warfarin In African Americans
- Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
- Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
- A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
- Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
- Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
- Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril
- Clopidogrel: A Case for Indication‐Specific Pharmacogenetics
- Warfarin Dosing in Patients With Impaired Kidney Function
- Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
Cited by
- Definition and validation of a patient-individualized physiologically-based pharmacokinetic model
- Update of genetic susceptibility in patients with Kawasaki disease
- The Significance of an Enhanced Concept of the Organism for Medicine
- Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.
- Human islets contain four distinct subtypes of β cells
- A New Paradigm. “Learn – Learn More”; Dose‐Exposure‐Response at the Center of Drug Development and Regulatory Approval
- Red blood cell distribution width as a risk factor for inhospital mortality in obstetric patients admitted to an intensive care unit: a single centre retrospective cohort study
- A superposable double-gradient droplet array chip for preparation of PEGDA microspheres containing concentration-gradient drugs
- Circulating steroid levels as correlates of adipose tissue phenotype in premenopausal women
- Three-dimensional poly(lactic-co-glycolic acid)/silica colloidal crystal microparticles for sustained drug release and visualized monitoring.
- Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait
- Circulating Oxidized Low‐Density Lipoprotein is a Strong Risk Factor for the Early Stage of Coronary Heart Disease
- Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment
- Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data.
- [Genetic and non-genetic factors of laboratory resistance to clopidogrel in patients with ischemic stroke].
- Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
- It’s time for sex in cognitive neuroscience
- Canine models of human cancer: Bridging the gap to improve precision medicine.
- Management of Patients Receiving Anticoagulation Therapy in Dental Practice: A Systematic Review
- Managing Manufacturing and Delivery of Personalised Medicine: Current and Future Models
Related papers
- VKORC1 and CYP2C9 genotypes are predictors of warfarin‐related outcomes in children
- Pharmacogenetics and pharmacogenomics: The impact of the single nucleotide polymorphisms in drug response
- Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients
- The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
- Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients
- The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients.
- The pharmacogenomics of warfarin safety and effectiveness in children
- Pharmacogenetics of acenocoumarol: CYP2C9 *2 and VKORC1 c.-1639G>A, 497C>G, 1173C>T, and 3730G>A variants influence drug dose in anticoagulated patients
- The pharmacogenetics of the response to warfarin in Chinese.